These results show asciminib’s effectiveness, including in almost 50% of ponatinib pretreated patients, and confirm its risk-benefit profile, supporting its use as a treatment option for T315I-mutated CML-CP. The gene discussed is CP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.